← Eichor
Condition: Msi H Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Msi H

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Canc
Phase 1 · 1 location(s) · West China Hospital · NCT07076823ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07270666DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With H
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770102PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsa
Phase 3 · 1 location(s) · Centre Hospitalier Universitaire Dijon · NCT06762405Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Phase 2 · 4 location(s) · Sun Yat-sen University · NCT03810339AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Phase 1 · 22 location(s) · Amgen · NCT07403721PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT05236972Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT03926338Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer
NA · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT04643041Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06903858A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06686576Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
NA · 1 location(s) · Jessica Mezzanotte Sharpe · NCT07555210The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cance
Phase N/A · 1 location(s) · Yunnan Cancer Hospital · NCT06477991KN035 for dMMR/MSI-H Advanced Solid Tumors
Phase 2 · 1 location(s) · 3D Medicines (Sichuan) Co., Ltd. · NCT03667170Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Me
Phase N/A · 20 location(s) · Federation Francophone de Cancerologie Digestive · NCT06353854Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Phase 1 · 1 location(s) · Allegheny Singer Research Institute (also known as Allegheny · NCT07001592Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
Phase 2 · 9 location(s) · Royal Marsden NHS Foundation Trust · NCT06250036Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
EARLY_Phase 1 · 1 location(s) · Massachusetts General Hospital · NCT07128355Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT04636008A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Phase 1/Phase 2 · 22 location(s) · Nimbus Wadjet, Inc. · NCT06898450Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
Phase 2 · 1 location(s) · University Medical Center Groningen · NCT05483400A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 an
Phase 2 · 39 location(s) · Ono Pharmaceutical Co., Ltd. · NCT06948448A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNO
Phase 1/Phase 2 · 16 location(s) · Merck Sharp & Dohme LLC · NCT02332668Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Phase 2 · 30 location(s) · BeiGene · NCT03736889Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or
Phase 2 · 5 location(s) · Emory University · NCT07140679KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT06099821FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 33 location(s) · Parabilis Medicines, Inc. · NCT05919264Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Col
Phase N/A · 2 location(s) · Geneplus-Beijing Co. Ltd. · NCT06098560A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
Phase 1 · 1 location(s) · Jemincare · NCT07208136
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.